We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » REPEAT QC VIOLATIONS COULD AFFECT KOS PRODUCT PIPELINE
REPEAT QC VIOLATIONS COULD AFFECT KOS PRODUCT PIPELINE
February 3, 2004
All products from Kos Pharmaceuticals could face more intense scrutiny from the FDA’s Metabolic and Endocrine Drug Products review division following a surprise inspection this summer that revealed a repeat quality control (QC) failure at the firm’s main manufacturing facility.